Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End
Executive Summary
Cephalon's $100 mil. in new financing from a preferred stock offering finalized on Aug. 13 will help tide the company over while it develops new indications for its lead drug, wakefulness agent Provigil.
You may also be interested in...
Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino
About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.
Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino
About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.
Abbott Gabitril
Cephalon will co-promote the anti-epileptic Gabitril (tiagabine) beginning in September. The company will increase its neurology sales force, which markets the narcolepsy therapy Provigil (modafinil), from 45 to 85 for the launch. Abbott also has an option to co-promote Provigil if Cephalon seeks a U.S. marketing partner